Jul 22, 2026 01:00AM
Jul 22, 2026 01:00AM
Jul 22, 2026 01:00AM
May 20, 2026 07:15AM
May 16, 2026 08:00AM
Feb 27, 2026 06:20AM
Jan 21, 2026 11:45AM Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma
Jan 13, 2026 12:19PM
Nov 7, 2025 08:50AM
Nov 7, 2025 08:42AM
Sep 19, 2025 07:59AM
Jul 24, 2025 01:41PM
Jun 20, 2025 06:19AM
May 6, 2025 01:30AM Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation
Apr 24, 2025 02:14AM
Sep 23, 2024 07:13AM
Jul 26, 2024 06:46AM
Jun 10, 2024 04:54PM
Jun 7, 2024 01:00AM
May 2, 2024 01:30AM
Apr 24, 2024 01:00AM Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
Feb 13, 2024 04:08PM
Dec 7, 2023 01:00AM
Nov 13, 2023 07:00AM
Oct 23, 2023 01:00AM
Sep 4, 2023 01:00AM
Sep 1, 2023 01:00AM
Aug 16, 2023 03:32PM US FDA approves Ipsen’s SohonosTM (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva
Jul 21, 2023 08:52AM
Jul 21, 2023 07:52AM
Jul 19, 2023 12:42PM
Jun 28, 2023 08:00PM
Jun 14, 2023 04:35PM
Jun 14, 2023 02:21PM
Jun 13, 2023 01:10PM U.S. FDA approves Bylvay® for patients living with cholestatic pruritus due to Alagille syndrome
Jun 12, 2023 01:00AM
May 26, 2023 08:20AM
Apr 27, 2023 01:00AM
Apr 24, 2023 02:00AM
Mar 16, 2023 02:02PM
Mar 2, 2023 02:13PM
Feb 15, 2023 01:00AM Ipsen, Université de Montréal and IRICoR broaden existing oncology partnership, with an exclusive license agreement and two new discovery-stage programs
Feb 13, 2023 05:00PM
Feb 9, 2023 01:00AM
Jan 27, 2023 01:00AM
Jan 20, 2023 10:00AM
Jan 9, 2023 01:00AM
Dec 23, 2022 05:00PM
Dec 8, 2022 04:05PM Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherap
Nov 9, 2022 06:57AM

1,208,022 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All